# Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder

> **NCT04878250** · PHASE2 · UNKNOWN · sponsor: **Queen Mary University of London** · enrollment: 49 (estimated)

## Conditions studied

- Transitional Cell Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** Bintrafusp alfa

## Key facts

- **NCT ID:** NCT04878250
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2023-07
- **Final completion:** 2025-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2021-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878250, "Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04878250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*